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Persistent bronchial inflammation in chronic obstructive pulmonary disease (COPD) is considered the cause of ventilation disorders 
and related contamination with conditionally pathogenic microorganisms; the latter can proceed and transform into a full infection, which can 
aggravate and exacerbate COPD.
The aim of the study was to evaluate the relations between the oropharyngeal microbiota in patients with COPD and the clinical, 
functional, and prognostic parameters of the disease.
Materials and Methods. 64 patients with COPD were included in the study; the participants were scheduled to visit our clinic on 
two occasions. In the first visit, their medical history was studied in detail and the major examination procedures were conducted. Those 
included an assessment of the respiratory function, the 6-minute walk test, the degree of dyspnea by the Medical Research Council scale, 
body plethysmography, the diffusion capacity of the lungs, and a chest CT scan. The second visit took place 12 months after the first one to 
assess the changes in the course of the disease. The result was considered negative if, in the second examination, the patient‘s condition 
was found more severe. Oropharyngeal samples of all patients were sequenced to identify the V3–V4 variable sites of the 16S rRNA gene.
Results. It is found that the microbiological oropharyngeal patterns in COPD patients depend on the source of micro-aspiration. In 
addition, the changes in the oropharyngeal microbiota correlate with the severity and prognosis of the disease, as well as the patient 
phenotype. Based on the data obtained by sequencing parts of the 16S rRNA gene, the role of oropharyngeal microbiota in determining the 
course and prognosis of COPD has been elucidated.
Conclusion. The presented clinical and functional characteristics associated with oropharyngeal microbiota indicate that micro-
aspirations from other body compartments not only affect the composition of oropharyngeal microbiota in patients with COPD but also have 
an important prognostic significance.
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Introduction
The development of ventilation disorders in chronic 
obstructive pulmonary disease (COPD) is manifested 
by a progressive decrease in airflow associated with an 
abnormal inflammatory response of the lungs to harmful 
particles [1, 2], including microorganisms [1]. At the 
same time, chronic bronchopulmonary inflammation and 
a decreased airflow create conditions for contamination 
of the respiratory tract by opportunistic and pathogenic 
flora that change the composition of the respiratory 
microbiota [1, 3]. In recent publications, the bacterial 
contamination of the bronchial tree in COPD has been 
implicated in the increasing risk of COPD transformation 
into an infectious process with its exacerbations and 
disease progression [3, 4]. However, the involvement 
of the respiratory microbiota associated with the COPD 
phenotype in this process is still debatable.
Thus, Chambers et al. [5] demonstrated that the 
microbiota in the respiratory tract of patients with 
predominantly severe COPD significantly differed from 
the bacterial composition of the airways in healthy 
individuals. In the COPD patients, there were less 
Bacteroides spp. and an increased representation 
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of Firmicutes and Proteobacteria. Similar results 
were obtained by Charlson et al. [6]. It has been also 
suggested that the abnormal changes in microbiota 
could be initiated at the perinatal period. Thus, 
Górecka D. and Puścińska E. [7] analyzed the 
composition of the respiratory tract microbiota in a 
newborn and its correlation with baby’s nutrition, and the 
use of antibiotics by the mother. The authors suggested 
their research would shed light on the causes of chronic 
pulmonary disorders. However, none of the published 
studies analyzed the respiratory microbiota in respect 
to the disease progression and its clinical/functional 
parameters [8–11]. This may be due to the fact that, 
firstly, COPD is a clinically heterogeneous disease, and 
secondly, determination of the microbiota composition 
using classical microbiological methods does not provide 
a complete picture of its composition.
In this study, we used the phenotypic classification 
of COPD based on clinical and functional differences 
between the patients. As compared with the 
determination of the forced expiratory volume (FEV1) 
alone, the proposed parameter better reflects the 
severity and prognosis of the disease. Here, the 
composition of microbiota was determined using 
the methods of molecular-genetic identification of 
microorganisms [1, 4], which significantly changed our 
knowledge about the oropharyngeal microbiome. The 
obtained results enabled us to propose a prognostic 
model to predict the severity of COPD based on the 
taxonomic composition of the oropharyngeal microbiota.
The aim of the study was to evaluate the relations 
between the oropharyngeal microbiota in patients 
with COPD and the clinical, functional, and prognostic 
parameters of the disease. 
Materials and Methods
This prospective non-interventional study included 64 
patients with COPD. The average age was 57 (50–63) 
years.
All patients had confirmed COPD according to the 
GOLD 2015 criteria [1, 2]; the diagnosis was made at 
least 12 months before the enrollment, and their smoking 
index was higher than 10 packs/year. For 4 weeks prior 
to the enrollment, they received no antibiotic therapy.
The study was conducted in accordance with the 
Helsinki Declaration (2013) and approved by the local 
Ethics Committee of the Siberian State Medical 
University (protocol No.1927 of 28.03.2011). An informed 
consent has been obtained from each patient.
The study included two patient visits. During the 
first visit, all patients were clinically examined and their 
relevant medical history was carefully studied (below we 
will refer to these patients as the extended examination 
group). Tolerance to exercise was determined using 
a 6-minute walk test. The degree of dyspnea was 
assessed by the MRC (Medical Research Council) 
scores; the external respiration was evaluated using the 
bronchodilation test and the pulmonary diffusion index 
(body plethysmography). The study was performed 
using a MasterScreen Body instrumentation (Erich 
Jaeger, Germany). The obtained data were compared 
to the reference values calculated by the generally 
accepted formulas recommended by the European 
Respiratory Society and American Thoracic Society. All 
patients underwent computed tomography scan of the 
chest (chest CT) with a Somatom Sensation 40 spiral CT 
scanner (Siemens, Germany). Densitometry of the lung 
tissue and bronchial structure was performed using the 
Pulmo CT program (Siemens, Germany). During the first 
visit, oropharyngeal swabs were taken from all patients.
Based on the clinical and functional parameters 
obtained at the examination, the patients were divided 
into groups according to three phenotypes of COPD: 
“chronic bronchitis” (n=30), “emphysema” (n=14), and 
“mixed” (n=20). This stratification was based on the 
emphysema and bronchitis phenotypes as proposed by 
Burrows (1966) and Dornhorst (1955) and modified by us.
The phenotype of “chronic bronchitis” describes 
patients whose major clinical symptom (aside from 
exacerbation periods) was cough with mucopurulent 
sputum. At auscultation, harsh breathing sounds and 
rales were detected; the chest CT showed signs of 
bronchitis, the diffusion lung capacity was normal.
The “emphysema” phenotype refers to patients 
whose major clinical symptom (aside from exacerbation 
periods) was shortness of breath; cough was mild and 
unproductive. At auscultation, a weakened vesicular 
breath with wheezing episodes was heard; the 
characteristic signs and a decreased diffusion capacity 
were present in the CT scans.
Patients, who showed no obvious signs of bronchitis 
or emphysema during non-exacerbation periods, were 
included in the “mixed” phenotype group.
During the second visit, which took place 12 months 
after the first one, all patients underwent a clinical 
and functional examination, an assessment of the 
exacerbation rate, an evaluation of dyspnea by the MRC 
scale, a determination of exercise tolerance and a test 
of external respiration using a bronchodilator probe. 
We analyzed the dynamics of COPD during the past 12 
months of observation, taking into account the severity 
of the symptoms, the post-bronchodilation value of 
FEV1 and the risk of exacerbations (GOLD 2015). The 
dynamics of the disease was considered negative if, at 
the second examination, the patient presented with a 
more severe course of COPD than he did on the first 
visit. The oropharyngeal samples were not taken during 
the second visit.
The Statistica 10.0 software package was used for 
statistical processing of the medical history data and 
the clinical/functional indices. When comparing the 
qualitative characteristics, the criterion χ2 was applied. 
To calculate the difference of the means between non-
paired samples, the Mann–Whitney U test was used. 
The qualitative data are presented as absolute or 
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relative (%) values. The quantitative data are presented 
as follows: those with a non-normal distribution — as Me 
[Q25; Q75]; and those with the normal distribution — 
as M±SD, where M is the arithmetic mean, SD is the 
standard deviation. The normality of distributions of 
was tested with the χ2 criterion. The difference of the 
means was considered statistically significant at p<0.05. 
The Spearman coefficient was used for the correlation 
analysis. The strength of the correlation was denoted 
as strong at ±0.7 to ±1; average at ±0.3 to ±0.699; and 
weak at 0 to ±0.299.
Samples of oropharyngeal swabs of all patients 
were tested for the presence of the 16S rRNA gene 
and the V3–V4 sites sequences according to the 
16S Metagenomic Sequencing Library Preparation 
protocol recommended by Illumina (USA) for the MiSeq 
sequencer. A taxonomic classification was carried 
out according to the sequence database of the 16S 
rRNA gene of Greengenes v. 13.5 with the help of the 
Bayesian classifier and the QIIME (Quantitative Insights 
into Microbial Ecology) software. To find taxonomic 
differences between the phenotype-
specified groups of samples at the 
level of the operating taxonomic 
unit (OTU), a method based on 
linear regression analysis and 
adjusted to the metagenome data 
by the metagenomeSeq package 
was used [12]. To detect clusters 
of microorganisms, the CoNet 
plugin version 1.1.beta [13] of the 
Cytoscape software was utilized. 
Correlations between the amounts 
of individual microorganisms 
were determined according to 
the Spearman method, only the 
correlations with a coefficient of 
0.05 or higher were considered. 
To quantify the impact of the 
oropharyngeal microbiota on COPD 
progression, a prognostic model was 
developed using the caret package, 
where the recursive elimination 
of variables with a 10-fold cross-
validation was applied.
Results and Discussion
In this study, a comparative 
intergroup analysis of the clinical 
and functional parameters of patients 
with different COPD phenotypes 
was performed. As a result, clinically 
important data were obtained to 
suggest that patients with the 
“mixed” phenotype of COPD had 
the most severe manifestations of 
the disease. Thus, in comparison 
with the two other phenotypes, “chronic bronchitis” and 
“emphysema”, patients with the “mixed” phenotype 
had more exacerbations per year and a higher value 
of the BODE index. The FEV1 values for the “mixed” 
phenotype were significantly lower than those for the two 
other phenotypes (see the Table).
The analyzed data indicated that patients with the 
“mixed” COPD phenotype were treated with inhalations 
recommended for patients with severe and extremely 
severe COPD: long-acting anticholinergic drugs + 
long-acting β2-agonists + inhaled glucocorticoids. In 
this group, the number of antibacterial therapy courses 
during the year was significantly higher as compared 
with the two other groups.
The composition of oropharyngeal microbiota in 
patients with different clinical and functional types of 
COPD was dominated by the Streptococcus, Veillonella, 
and Prevotella genera of microorganisms (10% and 
more) in all phenotypes of the disease (Figure 1). Our 
results on these “highly represented taxa” agree with the 
data reported by others [14–17].
Comparative characteristics of patients (the extended examination group) 
with different phenotypes of chronic obstructive pulmonary disease  
(Me [Q1; Q3])
Parameters











2.0 [1.0; 2.0] 2.0 [1.6; 2.0] 5.0 [3.8; 5.0] p1–2>0.05
p1–3<0.05
p2–3<0.0001
Existence of comorbid 
disorders (n/%)
7.0/23.3 3.0/21.4 16.0/80.0 p1–2>0.05
p1–3<0.001
p2–3<0.001
“Triple” therapy, per year 
(n/%)
1.0/3.3 1.0/7.1 9.0/45.0 p1–2<0.05
p1–3<0.0001
p2–3<0.0001
The number  
of antibacterial courses, 
per year
2.0 [1.0; 3.0] 1.0 [1.0; 1.8] 3.0 [1.8; 5.0] p1–2<0.05
p1–3<0.05
p2–3<0.0001
BODE index (scores) 2.0 [1.0; 2.0] 2.0 [1.0; 2.8] 5.0 [4.0; 6.0] p1–2>0.05
p1–3<0.05
p2–3<0.05
MRC (scores) 2.0 [1.0; 2.0] 2.0 [1.0; 2.8] 3.0 [2.0; 4.0] p1–2>0.05
p1–3<0.0001
p2–3=0.015
6-minute walk test (m) 500 [426; 518] 380 [348; 398] 308 [224; 376] p1–2<0.05
p1–3<0.05
p2–3<0.0001
FEV1 after bronchodilation 
(% of reference value)
68.5 [59.0; 71.0] 68.0 [58.0; 75.0] 48.0 [45.0; 49.0] p1–2>0.05
p1–3<0.05
p2–3<0.05
SpO2 after 6-minute walk 
(%)
98.0 [97.0; 99.0] 96.0 [95.0; 99.0] 94.0 [93.0; 95.0] p1–2>0.05
p1–3<0.05
p2–3<0.05
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The metagenomeSeq-assisted analysis of low-
represented taxa (less than 10% of the identified 
microbiome) revealed a predominance of bacterial 
commensals in patients with the phenotype of 
emphysema. Among those, the Firmicutes bacteria 
(Acidaminococcus LogFC 1.865; Anaerovibrio LogFC 
2.653; Leuconostoc LogFC 1.727; Oceanobacillus 
LogFC 1.107; Phascolarctobacterium LogFC 2.915; 
Tetragenococcus LogFC 1.513), the Actinobacteria 
bacteria (Micrococcus LogFC 1.002; Dermacoccus 
LogFC 2.191), and the Proteobacteria bacteria 
(Cardiobacterium LogFC 1.002; Novosphingobium 
LogFC 1.561) (p<0.001).
Analysis of the low-represented taxa in patients 
with the “chronic bronchitis” phenotype revealed a 
significant predominance of bacteria of Fusobacterium, 
Actinobacteria, Proteobacteria, Bacteroidetes, 
Firmicutes, Bacteroides, mainly due to a higher content 
of opportunistic bacteria of Haemophilus (LogFC 8.662), 
Actinomyces (LogFC 9.813), Lactobacillus (LogFC 
4.758), Leptotrichia (LogFC 10.556), Porphyromonas 
(LogFC 5.896), Bacillus (LogFC 3.161), Gemella (LogFC 
8.303) (p<0.001). Also in these patients, a considerable 
amount of opportunistic bacteria in the oropharynx 
was found: Prevotella melaninogenica species (LogFC 
11.738), Rothia mucilaginosa (LogFC 9.257), and 
Veillonella parvula (LogFC 10.631) (p<0.001).
Samples of oropharyngeal swabs from patients with 
COPD with the “mixed” phenotype showed the prevailing 
representation of the Firmicutes and Bacteroides 
bacteria (p<0.001) with a less diverse variety of species 
in comparison with the two other phenotypes.


































































Figure 1. Prevalent genera of microorganisms, comprising 
95% of the metagenome of the oropharyngeal microbiota in 
patients with chronic obstructive pulmonary disease (the 
extended examination group)
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oropharyngeal microbiota depends on the source of 
micro-aspiration (gastrointestinal tract, nasopharynx, 
oral cavity). Numerous studies [15, 18, 19] demonstrated 
the role of opportunistic oropharyngeal bacteria in 
the development of pneumonia and exacerbations of 
chronic bronchopulmonary diseases. These bacteria 
enter the lower respiratory tract as a result of micro-
aspiration from the upper respiratory tract. According to 
our study, 40% of patients with the “chronic bronchitis” 
phenotype and 70% with the “mixed” phenotype 
suffered from tonsillitis, sinusitis or periodontitis. In 
these patients, we detected the formation of clusters of 
oropharyngeal opportunistic bacteria: Fusobacterium + 
Prevotella + Mycoplasma + Bulleidia, Porphyromonas + 
Prevotella + Fusobacterium and Porphyromonas + 
Prevotella + Streptococcus minor. This finding supports 
the hypothesis that the aspirated oropharyngeal 
microflora transforms the composition of the airways 
microbiome in patients with the “mixed” and “chronic 
bronchitis” phenotypes of COPD.
High levels of bacteria typical for the gastrointestinal 
microbiota were found in oropharyngeal swabs 
from patients with the “emphysema” phenotype; 
that included a cluster of normal oropharyngeal 
microflora (such as Firmicutes) and Actinobacteria + 
Enterococcus (opportunistic gastrointestinal microbiota). 
Published [20, 21] studies have demonstrated that 
gastroesophageal reflux disease (GERD) is associated 
with chronic bronchopulmonary diseases, including 
COPD, thus aggravating the course of the main 
disease. In our study, GERD was found in 11 patients 
To identify the respiratory microbiota patterns 
associated with specific clinical and functional 
characteristics of the COPD patients, the Spearman’s 
correlation analysis was performed.
In the “chronic bronchitis” phenotype patients, 
a cluster of conditionally pathogenic bacteria was 
found; within the cluster, a strong positive correlation 
between the different microbial taxa was identified: 
Fusobacterium   +   Prevotella + Mycoplasma + Bulleidia 
(r=0.701; p<0.05).
In the COPD patients with the “emphysema” 
phenotype, a cluster of normal oropharyngeal microbiota 
of the Firmicutes type was found. In addition, an 
Actinobacteria cluster of opportunistic bacteria of the 
Enterococcus gastrointestinal type and strong positive 
intra-cluster correlations was also present (r>0.08, 
p<0.001 and r>0.08, p<0.05, respectively). 
In the “mixed” phenotype, two clusters of opportunistic 
oropharyngeal bacteria with a strong positive correlation 
were found: Porphyromonas + Fusobacterium + 
Prevotella (r=0.832, p<0.05) and Streptococcus + Rothia 
(r=0.761, p<0.05).
Thus, the patients with COPD showed three patterns 
of oropharyngeal microbiota composition. In patients 
with the “chronic bronchitis” phenotype, opportunistic 
bacteria were mostly represented. In patients with the 
“emphysema” phenotype, the oropharyngeal normobiota 
and intestinal microbiota (including conditionally-
pathogenic bacteria) were dominant. In patients with the 
“mixed” phenotype, a pattern with a low species diversity 
and a predominance of gastrointestinal opportunistic 
microbiota (Firmicutes), in combination 
with the opportunistic bacteria cluster 
(Porphyromonas + Prevotella + 
Fusobacterium) was found.
In this study, it was attempted, for the 
first time, to develop a prognostic model 
based on the clinical and functional 
phenotypes of COPD and their 
respective microbiological patterns. 
Our analysis indicates that an increase 
in the oropharyngeal Moraxellaceae, 
Peptococcaceae, Eubacteriaceae, 
Enterococcaceae, Staphylococcaceae, 
and Actinomycetaceae bacterial 
families is an unfavorable prognostic 
factor in terms of the disease 
progression. In the validation test, this 
model showed a sensitivity of 0.67 and 
specificity of 1, a prognosis accuracy of 
75% with an area under the ROS curve 
of 0.72 (Figure 2).
Thus, it can be argued that certain 
changes in the composition of 
oropharyngeal microbiota are significant 
for the progression of COPD.
To interpret the obtained results, we 
assumed that the composition of the 
Figure 2. Multiple correlations between different components of the 
oropharyngeal microbiota in patients with different prognoses of chronic 
obstructive pulmonary disease
The data includes variables with a Spearman correlation value of ≥0.05 at p<0.05 
after introducing the Benjamin–Hochberg correction for multiple comparisons. 
The blue diamond on the chart shows the optimal sub-selection of variables, 
which allows to classification of the patients with an accuracy of 76%
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(78.6%) with the phenotype of “emphysema”, in 
15 patients (75%) with the “mixed” phenotype, and 
only 6 patients (20%) with the phenotype of “chronic 
bronchitis”. It is known [14–17] that the presence of 
the Porphyromonas and Prevotellgenera pathogenic 
bacteria detected in patients with the “mixed” phenotype 
is clinically significant because this is associated with 
purulent inflammatory processes. Likewise, the impact 
of the respiratory tract opportunistic microflora on the 
pulmonary tissue is enhanced by the gastrointestinal 
microbiota that enters the airways. The low diversity of 
bacterial species in this COPD phenotype decreases 
their resistance to pathogens [17] and can severely 
complicate the course of COPD in patients with the 
“mixed” phenotype. 
The presented clinical and functional characteristics 
of COPD patients and their correlations with the 
composition of the oropharyngeal microbiota allow us 
to propose that micro-aspiration from different body 
compartments affects not only the oropharyngeal 
microbiota but also contributes to the phenotypic 
characterization and clinical prognosis of COPD. At 
present, it is difficult to ascertain, what are the primary 
factors determining the clinical and functional phenotype 
of COPD. They can be either the phenotypic traits of 
the disease (e.g., the impact of GERD) or a disorder 
of the upper respiratory tract or the composition of the 
oropharyngeal microbiota. Reasonably, a combination of 
the above factors should be considered.
As shown in the present study, the low species 
diversity of the oropharyngeal microbiota in patients with 
COPD of the “mixed” phenotype may favor progression 
and aggravation of the disease.
Conclusion
Each phenotype of chronic obstructive pulmonary 
disease with its specific clinical and functional features 
is characterized by a specific pattern of oropharyngeal 
microbiota, which determines the severity and prognosis 
of the disease. The bacterial composition of these 
patterns depends on the source of micro-aspiration 
(upper gastrointestinal tract or nasopharynx). In addition, 
the composition of the oropharyngeal microbiota is 
determined by the severity of the disease and by its 
phenotype. This phenotype determines the course of the 
disease in a patient with chronic obstructive pulmonary 
disease.
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